青年脑梗死和心肌梗死患者初次患病时不同危险因素研究

目的应用多元logistic回归分析模型探讨是否有一些重要的独立危险因素使患者更容易患脑梗死或心肌梗死。方法收集患者的人口基本数据和传统血管病危险因素,对患者进行常规血和生活检查,心电图和基本脑CT/MRI扫描。结果校正了混杂因素后发现,青年脑梗死患者独立的易感因素为:高血压、血清前白蛋白水平与饮酒。青年心肌梗死患者独立易感因素为:发病年龄、吸烟、血清白细胞与血糖水平。结论青年脑梗死和心肌梗死患者有着一些明显不同的易感因素。     

急性冠脉综合征患者RDW和MPV与心肌梗死的相关性研究

目的 研究急性冠脉综合征（ACS）患者红细胞体积分布宽度（RDW）和平均血小板体积（MPV）与心肌梗死的相关性。方法统计200例ACS患者RDW和MPV结果,分析心肌梗死与无心肌梗死患者差异,并与200例健康者对照。结果 ACS组RDW和MPV较对照组明显升高（P〈0.01）;ACS组心肌梗死与无心肌梗死患者RDW和MPV差异有统计学意义（P〈0.05）;RDW对心肌梗死诊断的灵敏度高,MPV特异性高。结论 RDW和MPV是临床简单、价廉的实验室测定项目,两者联用可作为ACS患者心肌梗死辅助诊断、监测指标。     

对国外电子期刊资源长期保存的解决方案

介绍电子期刊全文完整存档总体解决方案,具体阐述按照期刊字序导航实现资源完整存档的过程,并说明期刊分类简要信息采集与抽取、基本检索和引文或参考文献检索功能、重点学科全文完整存档界面设计。     

Preserving female fertility following cancer treatment: Current options and future possibilities

Children and women of reproductive age are increasingly surviving cancer diagnoses, and therefore long‐term quality‐of‐life issues are of greater importance at the time of diagnosis. Cancer therapies including radiation and chemotherapy can be detrimental to fertility, and therefore many patients are motivated to preserve fertility prior to cancer treatment. The only highly successful method in preserving fertility to date is embryo cryopreservation, which may not be appropriate for some patients due to age, delay in treatment, cancer type and stage, as well as availability of an acceptable sperm donor. Alternative methods including oocyte cryopreservation and ovarian tissue banking may also preserve fertility while providing additional flexibility to patients. In vitro ovarian follicle maturation following tissue banking is one potential approach that would not require a delay in cancer therapy for ovarian stimulation, would not require an immediate sperm donor, and does not carry the risk of reintroducing malignant cells following tissue transplantation. In vitro follicle culture systems have resulted in successful live births in the mouse. However, many challenges must be addressed in translating the system to the human. This review summarizes current approaches to fertility preservation and discusses recent developments and future challenges in developing a human in vitro follicle culture system. Pediatr Blood Cancer 2009;53:289–295. © 2009 Wiley‐Liss, Inc.     

蛋白酶激活受体-2对缺血再灌注大鼠心肌细胞凋亡的影响

Objective To investigate the effect of protease-activated receptor2 (PAR-2) on rat apoptotic cardiomyocytes underwent iachemia reperfusion (I/R) injury. Methods Healthy male Sprague-Dawley rats were randomly divided into five groups (n = 8 each): sham-operation group, I/R (ligating the left coronary artery for 30 minutes and followed by 120 minutes reperfusion) group and three SLIGRL-NH2 groups treated with intravenous PAR-2 agonist SLIGRL-NH2 at different doses (0.5,1,3 mg/kg) 5 minutes before reperfusion. Apoptic cardiomyocytes was detected by TUNEL staining and by DNA ladder on agarose gel electrophoresis. Bax and Bcl-2 expression in myocardium was analyzed by immunohistochemical technique. The mRNA expression of PAR-2 was determined by Real-time quantitative polymerase chain reaction(RT-PCR). Results (1) The apoptosis index and the expression of Bcl-2 and Bax were significantly increased in IR group and SLIGRL-NH2 groups than those in sham group (P<0. 05～0.01). (2) Compared with I/R group, the apoptosis index and the expression of Bax were significantly reduced while the expression of Bcl-2 and PAR-2 mRNA were significantly upregnlated by SLIGRL-NH2 in a dose-dependent manner. (3) DNA Agarose gel electrophoresis demonstrated that DNA ladder existed in I/R and 0.5 mg/kg SLIGRL-NH2 group, but not in 1,3 mg/kg SLIGRL-NH2 groups. Conclusions PAR-2 agonist SLIGRL-NH2 could reduce myocardial apoptosis by upregulating the Bcl-2 and PAR-2 mRNA level and downregnlating Bax expression in a dose-dependent manner in this rat I/R model.     

Has hyperglycemia a different prognostic role in STEMI patients with or without diabetes?

Background and aimsHyperglycemia at hospital admission is a common finding in patients with STEMI. However, whether elevated acute glycemia in these patients may have a direct impact on worsening prognosis or is just a marker of a greater neurohormonal activation in response to the infarction is still unsettled.We sought to investigate the prognostic impact of hyperglycemia at hospital admission in patients undergoing primary PCI (pPCI) for STEMI, and the influence of the presence of diabetes mellitus (DM) on its prognostic impact.Methodsand Results, We enrolled 2958 consecutive STEMI patients treated by pPCI. Hyperglycemia was defined as plasma glucose >198 mg/dL (or >11 mmol/L). Patients with hyperglycemia showed a greater risk-profile; they also experienced a higher mortality both at univariable (17.6% vs 5.2%, p < 0.001) and multivariable (HR 1.9, 95%IC 1.5–2.9, p = 0.001) analysis. However, after stratification for DM presence, hyperglycemia resulted as an independent predictor of mortality only in patients without DM (HR 2, 95%IC 1.2–3.4, p = 0.01).ConclusionHyperglycemia in the setting of myocardial infarction treated with primary PCI in an independent predictor of all-cause mortality in patients without diabetes; in patients with diabetes, its prognostic impact seems attenuated.     

Internet and cardiovascular research: the present and its future potentials and limits

The Internet and the World Wide Web have been proposed as tools to improve medical and cardiovascular research. These new technologies have been mainly applied to large-scale clinical trials, with the development of clinical-trial websites. They include tools for the management of some aspects of clinical trials, such as the dissemination of information on trial progress; randomisation and the monitoring processes; the distribution and accountability of study drugs; and remote data-entry. Several clinical-trial websites have been developed in the cardiovascular field over the last few years, but few have been designed to conduct trials fully online. Advantages of such systems include greater interaction between the coordinating centre and investigators, availability of a clean database in a short time, and cost reduction. Website developers need to take care of security issues and to use security tools (data encryption, firewalls, passwords and electronic signatures) in order to prevent unauthorised users from accessing the system and patient data.